The positive TP53 AML data is a strong pipeline catalyst for this micro-cap biotech, but the simultaneous registration of 6.4M+ shares for resale by three large warrant holders creates an extreme overhang. Traders should watch for near-term selling pressure from the selling stockholders, which could cap any upside from the clinical news. The next key catalyst is the stockholder approval needed to make the Common Warrants and Inducement Warrants exercisable.
Price Chart
Executive Summary
Aptevo Therapeutics filed an 8-K announcing a 93% clinical benefit rate with its mipletamig triplet in frontline AML patients with TP53 mutations, a historically difficult-to-treat population. This positive clinical data was filed alongside a 424B4 prospectus registering up to 6,444,858 shares for resale by selling stockholders (Armistice, Hudson Bay, Sabby) from an August 12, 2026 warrant inducement and private placement that raised approximately $4.5 million in gross proceeds. The clinical catalyst is significant for a $5M market cap biotech, but the massive potential dilution (the registered resale shares represent ~3.6x the current 1.81M shares outstanding) creates a powerful countervailing overhang, resulting in a mixed sentiment with notable impact.
Key Facts
- Aptevo announced a 93% clinical benefit rate with mipletamig triplet in evaluable frontline AML patients with TP53 mutations.
- Filed a 424B4 prospectus registering up to 6,444,858 shares for resale by Armistice Capital, Hudson Bay, and Sabby Volatility Warrant Master Fund.
- The registered shares are issuable upon exercise of Pre-Funded Warrants (861,708), Common Warrants (4,308,540), and Inducement Warrants (1,274,610) from an August 12, 2026 transaction.
- The August 12, 2026 inducement and private placement raised approximately $4.5 million in gross proceeds.
- As of August 21, 2026, there were 1,810,215 shares of common stock outstanding; the 6,444,858 registered resale shares represent ~356% of current outstanding shares.
- On September 2, 2026, the last reported sale price of APVO common stock was $2.60 per share.
- The company's audited financial statements include an explanatory paragraph related to a going concern uncertainty.
- As of June 30, 2026, stockholders' equity was $6.0 million.
- The company faces potential delisting risk from Nasdaq if it fails to maintain compliance with continued listing requirements, including a $1.00 minimum bid price and a $5 million market value of listed securities requirement.
Financial Impact
Approximately $4.5 million in gross proceeds raised from the August 12, 2026 warrant inducement and private placement. The 424B4 registers up to 6,444,858 shares for resale, representing massive potential dilution (~356% of current 1.81M shares outstanding).
Risk Factors
- Massive potential dilution from up to 6,444,858 registered resale shares, representing ~356% of current outstanding shares.
- Nasdaq delisting risk due to low bid price ($2.60) and potential failure to meet the $5 million market value of listed securities requirement.
- Going concern uncertainty noted in the auditor's report.
- Clinical-stage biotech with no approved products and a history of operating losses.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B4 Filing (APVO) — Batch item 1 | 0001193125-26-381149 |
| Document: 0001193125-26-381149-index-headers.html | 0001193125-26-381098 |
| Document: 0001193125-26-381149-index.html | 0001193125-26-381149 |
| Document: 0001193125-26-381149.txt | 0001193125-26-381149 |
| 8-K Filing (APVO) — Batch item 5 | 0001193125-26-381098 |
| 424B4 Filing (APVO) — Batch item 6 | 0001193125-26-381149 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 8-K | $1.73 | awaiting T+5 | — | $1.73 (−0.10%) |
Oct 23, 2026 2d ago | 8-K | $1.61 | awaiting T+5 | — | $1.73 (+7.45%) |
Oct 14, 2026 12d ago | 8-K | $1.73 $1.60 | ▼ −7.51% | ▼ −7.97% | $1.73 (+0.00%) |
Sep 24, 2026 4w ago | 8-K | $1.83 $1.76 | ▼ −3.83% | ▼ −3.41% | $1.73 (−5.46%) |
Sep 3, 2026 7w ago | 424B4 / 8-K | $1.71 $1.82 | ▲ +6.43% | ▲ +7.58% | $1.73 (+1.17%) |
Sep 3, 2026 7w ago | EFFECT | $1.71 $1.82 | ▼ −6.43% | ▼ −7.58% | $1.73 (−1.17%) |
Aug 14, 2026 10w ago | 8-K | $2.94 $2.68 | ▼ −8.84% | ▼ −7.48% | $1.73 (−41.16%) |
Jul 27, 2026 12w ago | 8-K | $4.21 $3.95 | ▼ −6.18% | ▼ −8.44% | $1.73 (−58.91%) |
Jun 30, 2026 16w ago | 8-K | $4.45 $4.51 | ▲ +1.35% | ▲ +1.09% | $1.73 (−61.12%) |
May 6, 2026 24w ago | 8-K | $4.86 $4.76 | ▼ −2.06% | ▼ −3.56% | $1.73 (−64.40%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers